Analysis among cognitive profiles and gray matter volume in newly diagnosed Parkinson's disease with mild cognitive

Sang Woo Noh1, Yong Hee Han2, Chi Woong Mun2

  • 1Department of Neurology, Bussan Paik Hospital, Inje University College of Medicine, Bussan, South Korea.

Abstract

Insights

Newly diagnosed Parkinson's disease with mild cognitive impairment (PD-MCI) shows verbal memory deficits and reduced gray matter volume in frontal and temporal areas. These findings help differentiate PD-MCI from Parkinson's disease with normal cognition (PD-NC).

Area of Science:

  • Neuroscience
  • Neurology
  • Radiology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder affecting motor function.
  • Mild cognitive impairment (MCI) is common in PD, impacting daily life.
  • Understanding early cognitive changes in de novo, drug-naïve PD is crucial for timely intervention.

Purpose of the Study:

  • To characterize neuropsychological profiles in de novo, drug-naïve Parkinson's disease with mild cognitive impairment (PD-MCI).
  • To analyze gray matter (GM) volume differences in PD-MCI compared to Parkinson's disease with normal cognition (PD-NC) and healthy controls (HC).

Main Methods:

  • Fifty-two newly diagnosed PD patients underwent neuropsychological testing to define PD-MCI and PD-NC groups.
  • Brain MRI scans were acquired for PD patients and HC.
  • Gray matter (GM) volume analysis was performed to compare groups.

Main Results:

  • PD-MCI patients exhibited significantly worse performance in clinical dementia rating, global deterioration scale, and verbal memory compared to PD-NC.
  • Reduced GM volume was observed in the right hippocampus, cuneus, and precuneus in PD-NC versus HC.
  • PD-MCI showed decreased GM volume in bilateral temporal and frontal areas compared to HC, and in specific regions like the right temporal pole and medial frontal gyrus compared to PD-NC.

Conclusions:

  • Clinical dementia ratings and global deterioration scales can distinguish PD-MCI from PD-NC.
  • Verbal memory impairment is a key cognitive deficit in de novo PD-MCI, linked to posterior cortical areas.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
6
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
5
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
4
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K